US 10023614
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
granted A61KA61K38/00A61P
Quick answer
US patent 10023614 (Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases) held by Protagonist Therapeutics, Inc. expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Protagonist Therapeutics, Inc.
- Grant date
- Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K38/00, A61P, A61P1/00, A61P1/04